Condition
Chronic Allergic Conjunctivitis
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
100%
4 of 4 completed with results
Key Signals
4 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (2)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02988882Phase 3CompletedPrimary
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
NCT02062905Phase 2CompletedPrimary
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
NCT01730872Phase 4CompletedPrimary
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
NCT02445326Phase 3CompletedPrimary
OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Showing all 4 trials